| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 43.32B | 40.27B | 42.54B | 32.47B | 37.53B | 32.32B |
| Gross Profit | 31.46B | 27.22B | 26.93B | 20.69B | 26.72B | 21.21B |
| EBITDA | 14.08B | 10.61B | 4.06B | 9.94B | 13.86B | 11.07B |
| Net Income | 11.04B | 8.21B | 4.10B | 5.97B | 7.73B | 5.90B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 245.04B | 297.64B | 293.70B | 258.14B | 233.75B |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 5.40B | 22.41B | 5.24B | 12.63B | 8.26B |
| Total Debt | 0.00 | 115.07B | 162.28B | 159.39B | 134.98B | 123.69B |
| Total Liabilities | -102.30B | 142.74B | 187.08B | 181.01B | 151.89B | 136.99B |
| Stockholders Equity | 102.30B | 97.28B | 84.91B | 81.36B | 76.86B | 70.00B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 55.35B | 24.61B | -25.73B | -32.20B | 9.63B |
| Operating Cash Flow | 0.00 | 55.69B | 25.15B | -24.49B | -32.03B | 9.69B |
| Investing Cash Flow | 0.00 | -24.75B | -20.90B | -4.51B | 26.16B | -22.49B |
| Financing Cash Flow | 0.00 | -47.86B | 1.62B | 21.53B | 10.24B | 12.96B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
66 Neutral | ₹158.25B | 14.33 | ― | 3.05% | -10.92% | 152.70% | |
66 Neutral | ₹229.09B | 26.68 | ― | ― | 8.01% | -20.87% | |
62 Neutral | ₹86.74B | 73.79 | ― | ― | 8.35% | -50.99% | |
58 Neutral | ₹189.59B | 24.01 | ― | 0.10% | 43.41% | 109.52% | |
55 Neutral | ₹104.87B | 24.29 | ― | 1.35% | -19.77% | -11.03% | |
55 Neutral | ₹95.24B | 21.23 | ― | 0.57% | 35.30% | 41.06% |
JM Financial Limited has disclosed a settlement order issued by the Securities and Exchange Board of India (SEBI) concerning suo-motu settlement applications filed by the company and its subsidiaries. The settlement, which neither admits nor denies the findings, addresses potential enforcement proceedings for regulatory violations. The company has stated that there is no material impact on its financial or operational activities as a result of this settlement.